FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317863021> ?p ?o ?g. }

• W4317863021 endingPage "531" @default.
• W4317863021 startingPage "531" @default.
• W4317863021 abstract "531 Background: At the primary analysis of TOPAZ-1 (NCT03875235; data cut-off [DCO] Aug 11, 2021), durvalumab (D) + gemcitabine and cisplatin (GC) significantly improved overall survival (OS) vs placebo (PBO) + GC in participants (pts) with advanced biliary tract cancer (BTC), with OS curves that separated over time (Oh et al. NEJM Evid 2022), that persisted with further follow-up (DCO Feb 25, 2022; HR, 0.76 [95% CI, 0.64–0.91]; 18-month OS, 34.8% [D + GC] vs 24.1% [PBO + GC]; Oh et al. Ann Oncol 2022 Abs 56P). We characterized long-term survivors (LTS) in TOPAZ-1. Methods: Pts untreated for unresectable locally advanced, recurrent or metastatic BTC received D (1500 mg every 3 weeks [Q3W]) or PBO, + G (1000 mg/m 2 ) and C (25 mg/m 2 ) on days 1 and 8 Q3W, up to 8 cycles, followed by D (1500 mg Q4W) or PBO. Characteristics and outcomes of LTS (pts who survived ≥18 months after randomization; DCO Feb 25, 2022) were assessed. Results: There were more LTS with D + GC vs PBO + GC (Table). Characteristics of LTS were consistent with the full analysis set (FAS, all randomized pts) including age, sex, region, primary tumor location, disease classification (metastatic vs locally advanced) and PD-L1 expression. Recurrent disease was more common than initially unresectable disease in LTS vs FAS. Median exposure to study treatment was 11.3 months (mo; D), 9.7 mo (PBO) and 5.5 mo (GC, both arms) in LTS and 7.3 mo (D), 5.8 mo (PBO) and 5.1 mo (GC, both arms) in FAS. The objective response rate in LTS was greater with D + GC vs PBO + GC (44.3%, D + GC; 33.8%, PBO + GC), and greater for both groups vs FAS (26.7%, D + GC; 18.7%, PBO + GC). A higher proportion of LTS in the PBO + GC group received subsequent anticancer therapy, including immunotherapy, than LTS in the D + GC group. The frequency of treatment-related adverse events leading to discontinuation in LTS was consistent with FAS. Conclusions: In TOPAZ-1, characteristics of LTS were generally consistent with the FAS. Overall, LTS were more common with D + GC; LTS in the PBO + GC group appear to be associated with higher frequency of subsequent treatments, including immunotherapy. Clinical trial information: NCT03875235 . [Table: see text]" @default.
• W4317863021 created "2023-01-25" @default.
• W4317863021 creator A5005580223 @default.
• W4317863021 creator A5010988090 @default.
• W4317863021 creator A5016033095 @default.
• W4317863021 creator A5026250495 @default.
• W4317863021 creator A5032910854 @default.
• W4317863021 creator A5043672686 @default.
• W4317863021 creator A5043962640 @default.
• W4317863021 creator A5045587524 @default.
• W4317863021 creator A5053209984 @default.
• W4317863021 creator A5059766169 @default.
• W4317863021 creator A5072308451 @default.
• W4317863021 creator A5077826150 @default.
• W4317863021 creator A5079645039 @default.
• W4317863021 creator A5079728501 @default.
• W4317863021 creator A5083719549 @default.
• W4317863021 creator A5084399437 @default.
• W4317863021 creator A5091106115 @default.
• W4317863021 date "2023-02-01" @default.
• W4317863021 modified "2023-10-16" @default.
• W4317863021 title "Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer." @default.
• W4317863021 doi "https://doi.org/10.1200/jco.2023.41.4_suppl.531" @default.
• W4317863021 hasPublicationYear "2023" @default.
• W4317863021 type Work @default.
• W4317863021 citedByCount "2" @default.
• W4317863021 countsByYear W43178630212023 @default.
• W4317863021 crossrefType "journal-article" @default.
• W4317863021 hasAuthorship W4317863021A5005580223 @default.
• W4317863021 hasAuthorship W4317863021A5010988090 @default.
• W4317863021 hasAuthorship W4317863021A5016033095 @default.
• W4317863021 hasAuthorship W4317863021A5026250495 @default.
• W4317863021 hasAuthorship W4317863021A5032910854 @default.
• W4317863021 hasAuthorship W4317863021A5043672686 @default.
• W4317863021 hasAuthorship W4317863021A5043962640 @default.
• W4317863021 hasAuthorship W4317863021A5045587524 @default.
• W4317863021 hasAuthorship W4317863021A5053209984 @default.
• W4317863021 hasAuthorship W4317863021A5059766169 @default.
• W4317863021 hasAuthorship W4317863021A5072308451 @default.
• W4317863021 hasAuthorship W4317863021A5077826150 @default.
• W4317863021 hasAuthorship W4317863021A5079645039 @default.
• W4317863021 hasAuthorship W4317863021A5079728501 @default.
• W4317863021 hasAuthorship W4317863021A5083719549 @default.
• W4317863021 hasAuthorship W4317863021A5084399437 @default.
• W4317863021 hasAuthorship W4317863021A5091106115 @default.
• W4317863021 hasConcept C121608353 @default.
• W4317863021 hasConcept C126322002 @default.
• W4317863021 hasConcept C142724271 @default.
• W4317863021 hasConcept C204787440 @default.
• W4317863021 hasConcept C27081682 @default.
• W4317863021 hasConcept C2776694085 @default.
• W4317863021 hasConcept C2777701055 @default.
• W4317863021 hasConcept C2777742743 @default.
• W4317863021 hasConcept C2778239845 @default.
• W4317863021 hasConcept C2780030458 @default.
• W4317863021 hasConcept C2780258809 @default.
• W4317863021 hasConcept C2989005 @default.
• W4317863021 hasConcept C3017919176 @default.
• W4317863021 hasConcept C71924100 @default.
• W4317863021 hasConcept C90924648 @default.
• W4317863021 hasConceptScore W4317863021C121608353 @default.
• W4317863021 hasConceptScore W4317863021C126322002 @default.
• W4317863021 hasConceptScore W4317863021C142724271 @default.
• W4317863021 hasConceptScore W4317863021C204787440 @default.
• W4317863021 hasConceptScore W4317863021C27081682 @default.
• W4317863021 hasConceptScore W4317863021C2776694085 @default.
• W4317863021 hasConceptScore W4317863021C2777701055 @default.
• W4317863021 hasConceptScore W4317863021C2777742743 @default.
• W4317863021 hasConceptScore W4317863021C2778239845 @default.
• W4317863021 hasConceptScore W4317863021C2780030458 @default.
• W4317863021 hasConceptScore W4317863021C2780258809 @default.
• W4317863021 hasConceptScore W4317863021C2989005 @default.
• W4317863021 hasConceptScore W4317863021C3017919176 @default.
• W4317863021 hasConceptScore W4317863021C71924100 @default.
• W4317863021 hasConceptScore W4317863021C90924648 @default.
• W4317863021 hasIssue "4_suppl" @default.
• W4317863021 hasLocation W43178630211 @default.
• W4317863021 hasOpenAccess W4317863021 @default.
• W4317863021 hasPrimaryLocation W43178630211 @default.
• W4317863021 hasRelatedWork W1217647967 @default.
• W4317863021 hasRelatedWork W1970498696 @default.
• W4317863021 hasRelatedWork W1996347414 @default.
• W4317863021 hasRelatedWork W2049822713 @default.
• W4317863021 hasRelatedWork W2115261608 @default.
• W4317863021 hasRelatedWork W2328187296 @default.
• W4317863021 hasRelatedWork W2999610576 @default.
• W4317863021 hasRelatedWork W4206916678 @default.
• W4317863021 hasRelatedWork W4236804026 @default.
• W4317863021 hasRelatedWork W4242359032 @default.
• W4317863021 hasVolume "41" @default.
• W4317863021 isParatext "false" @default.
• W4317863021 isRetracted "false" @default.
• W4317863021 workType "article" @default.